Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy

Oncologist

Volumn 12, Issue 6, 2007, Pages 636-643

  Tacca, Olivier ^a,b   Penault Llorca, Frédérique ^a,b,c   Abrial, Catherine ^a,b   Mouret Reynier, Marie Ange ^a   Raoelfils, Inès ^a   Durando, Xavier ^a,b   Achard, Jean Louis ^a   Gimbergues, Pierre ^a   Curé, Hervé ^b,c,d,e   Chollet, Philippe ^a,b,c,d  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre d'Investigation Clinique   (France)

^e INSTITUT JEAN GODINOT   (France)

Author keywords

Allred score; Breast cancer; Hormone receptor status; Neoadjuvant chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; NAVELBINE; PIRARUBICIN; TAXANE DERIVATIVE; TAXOBEL; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR BIOPSY;

BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID;

EID: 34447117507     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-6-636     Document Type: Article

References (20)

1. Buchholz TA, Hunt KK, Whitman GJ et al. Neoadjuvant chemotherapy for breast carcinoma: Multidisciplinary considerations of benefits and risks. Cancer 2003;98(6):1150-1160.
2. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146.
3. Di Leo A, Dowsett M, Horten B et al. Current status of HER2 testing. Oncology 2002;63(suppl 1):25-32.
4. Miyoshi Y, Kim SJ, Akazawa K et al. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res 2004;10:8163-8169.
5. Arpino G, Weiss HL, Clark GM et al. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005;23:4585-4587.
6. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
7. Nicolini A, Giardino R, Carpi A et al. Metastatic breast cancer: An updating. Biomed Pharmacother 2006;60:548-556.
8. Abrial SC, Penault-Llorca F, Delva F et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: A retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 2005;94:255-263.
9. Belembaogo E, Feillel V, Chollet P et al. J Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 1992;28A:896-900.
10. Chollet P, Charrier S, Brain E et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 1997;33:862-866.
11. Chollet P, Amat S, Penault-Llorca F et al. High pathological response rate induced by primary docetaxel monotherapy in operable breast cancer. Breast Cancer Res Treat 2000;64:251a.
12. Van Praagh I, Amat S, Delva R et al. Induction chemotherapy in operable breast cancer by NET regimen: Multicentric phase II trial (Meeting abstract). Proc Am Soc Clin Oncol 2001;20:1889a.
13. Van Praagh I, Curé H, Leduc B et al. Efficacy of a primary regimen combining vinorelbine, epirubicin, and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist 2002;7:418-423.
14. Amat S, Penault-Llorca F, Cure H et al. Scarff-Bloom-Richardson (SBR) grading: A pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791-796.
15. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
16. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2001;(1):CD000486.
17. Davis BW, Zava DT, Locher GW et al. Receptor heterogeneity of human breast cancer as measured by multiple intratumoral assays of estrogen and progesterone receptor. Eur J Cancer Clin Oncol 1984;20:375-382.
18. Mann GB, Fahey VD, Feleppa F et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005;23:5148-5154.
19. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. The Oncologist 2004;9:606-616.
20. Yang X, Phillips DL, Ferguson AT et al. Synergistic activation of functional estrogen receptor (ER)-α by DNA methyltransferase and histone deacetylase inhibition in human ER-α-negative breast cancer cells. Cancer Res 2001;61:7025-7029.